Molecular docking analysis of tetracyclic triterpenoids from Cassia fistula L. with targets for diabetes mellitus

Indu Sabapathy¹, ³, Ireen Christopher¹, ³, Vijayalakshmi Periyasamy¹ & Rajalakshmi Manikkam¹, ², ³,*

¹DBT-BIF Centre, Holy Cross College (Autonomous), Tiruchirappalli, Tamil Nadu, India; ²Department of Zoology, Holy Cross College (Autonomous), Tiruchirappalli, Tamil Nadu, India; ³Department of Biotechnology, Holy Cross College (Autonomous), Tiruchirappalli, Tamil Nadu, India; *Corresponding author - Dr. Rajalakshmi Manikkam; Phone: +91-9952498098

Author contacts:
Indu Sabapathy - E-mail: sabaindhu2010@gmail.com
Ireen Christopher - E-mail: ireentrichy@gmail.com
Vijayalakshmi Periyasamy - E-mail: pvijibi@gmail.com
Rajalakshmi Manikkam - E-mail: rajalakshmi@hcctrichy.ac.in, mdraji@gmail.com

Abstract:
It is of interest to develop effective drugs for diabetes mellitus. We document the molecular docking analysis data of tetracyclic-triterpenoids from Cassia fistula L. with targets for diabetes mellitus.
Molecular docking is a crucial approach in computer-aided drug design that has been increasingly popular in recent years for quickly predicting the binding mechanisms and affinities of small molecules to their target molecules [1]. Tetracyclic triterpenoids are active components present in a variety of higher plants that have been studied extensively for their potential to treat diabetes and associated complications [2]. The hypoglycemic action of these tetracyclic triterpenoid compounds was previously reported in our study [3]. Therefore, it is of interest to document the molecular docking analysis data of tetracyclic triterpenoids from Cassia fistula L., with targets for diabetes mellitus involved in glycolysis, gluconeogenesis, glycogenolysis, de novo lipogenesis, insulin secretion and sensitivity, activation of incretin hormones, reabsorption of intestinal glucose from carbohydrate metabolism and peripheral glucose uptake (Table 1).

**Table 1: Molecular receptors focused as targets for diabetes treatment**

| Targets | Mechanism of action of drugs in maintaining glucose homeostasis | Experimental and in-silico evidences | References |
|---------|-------------------------------------------------------------|-------------------------------------|------------|
| Glucokinase | Glucokinase activators improves the glycemic control through hepatic glucose metabolism and pancreatic insulin secretion | The phytoconstituents of Eucnostenema littorale showed promising glucokinase enzyme activation efficacy | [4] |
| Glycogen phosphorylase | Glycogen phosphorylase inhibitors restrains the enzymatic synthesis of glucose from glycogen thus lowering the rise in blood glucose | y-streptol isolated from Lippia nodiflora showed good anti diabetic effect by increasing glucokinase activity | [5] |
| Peroxisome proliferator-activated receptor gamma | Peroxisome proliferator-activated receptor gamma agonists restores glucose and lipid metabolism | Active chemical constituents of Timospora cordifolia showed good binding affinity with catalytic site of the enzyme | [6] |
| Insulin receptor kinase | Insulin receptor kinase activators regulates the signal transduction via PI3K-AKT pathway | Bioactive molecules from traditional plants virtually screened for Peroxisome proliferator-activated receptor gamma activation | [7] |
| Protein Phosphatase 1B Tyrosine | Protein Tyrosine Phosphatase 1B inhibitors prevents the dephosphorylation of insulin receptor which in turn promotes insulin signaling | Flavonoids from banana flower explored as potential insulin receptor tyrosine kinase activators | [8] |
| Dipeptidyl peptidase (IV) | Dipeptidyl peptidase (IV) inhibitors prevent the degradation of the incretin hormones (GIP and GLP-1), thereby stimulating insulin secretion from pancreatic β-cells and decreasing blood glucose levels | The naturally isolated compounds Morus alba root exhibited PTP1B inhibitory activity | [9] |
| Glycogen synthase kinase 3 | Reduces glycogen synthesis by phosphorylating glycogen synthase | Compounds from Curculigo latifolia inhibited the DPP (IV) enzyme in the gut, increasing insulin production and lowering glucose levels in the bloodstream. | [10] |
| α-glucosidase | α-glucosidase inhibitors inhibits the absorption of complex carbohydrates into the intestine and reduces the postprandial blood glucose levels | Piperazine-derived compounds evaluated as inhibitors for DPP (IV) enzyme | [11] |

**Table 2: Receptor-ligand interactions of triterpenoid compounds with diabetic targets**

| Ligand | Target | Binding affinity score (kcal/mol) | H-bond interactions |
|--------|--------|----------------------------------|---------------------|
| Cpd-1 | Glucokinase | -6.8 | Asp 205, Thr 222, Gly 230 |
| | Glycogen phosphorylase | -9.1 | Glu 382 |
| | Peroxisome proliferator-activated receptor gamma | -7.7 | Lys 474 |
| | Insulin receptor kinase | -8.3 | Gly1132, Met1153 |
| | Dipeptidyl peptidase (IV) | -8.5 | Thr335, Gly335 |
| | Protein Tyrosine Phosphatase 1B | -7.3 | Glu 276 |
| | α-glucosidase | -9.1 | Asp 379, Val 380, Lys 398, Gly 399 |
| | Glycogen synthase kinase 3β | -7.6 | Glu 97 |
| | Glucokinase | -7.3 | Arg 186 |
| | Glycogen phosphorylase | -8.8 | Gln 71, Tyr 155 |
| | Peroxisome proliferator-activated receptor gamma | -8.1 | Lys 465 |
| | Insulin receptor kinase | -7.9 | His 1330, Asp 1332, Tyr 1162 |
| | Dipeptidyl peptidase (IV) | -9.1 | Arg 669 |
| | Protein Tyrosine Phosphatase 1B | -7.6 | Arg 324 |
| | α-glucosidase | -8.1 | Val 380 |
| | Glycogen synthase kinase 3β | -7.9 | Lys 85 |
| | Glucokinase | -6.9 | Asn 203, Glu 290 |
| | Glycogen phosphorylase | -9.3 | Tyr 155, Arg 310 |
| | Peroxisome proliferator-activated receptor gamma | -6.7 | Leu 465 |
| | Insulin receptor kinase | -7.8 | Trp 1200 |
| | Dipeptidyl peptidase (IV) | -9.1 | Arg 669 |
| | Protein Tyrosine Phosphatase 1B | -7.3 | His 60, Gln 61 |
| | α-glucosidase | -7.9 | Val 380 |
| | Glycogen synthase kinase 3β | -7.4 | Leu 86, Glu 97 |
| | Glucokinase | -8 | Gln 110, Thr 332, Arg 333 |
| | Glycogen phosphorylase | -8.9 | Tyr 155, Arg 242, Arg 310 |
| | Peroxisome proliferator-activated receptor gamma | -8.7 | Lys 275 |
| | Insulin receptor kinase | -8.6 | Arg 1000, Ala 1089, Asp1083 |
| | Dipeptidyl peptidase (IV) | -9.1 | Thr 335, Ser 376, Asp 588 |
| | Protein Tyrosine Phosphatase 1B | -7.3 | Glu 26, Lys 248, Lys 255 |
| | α-glucosidase | -8.1 | Asn 64 |
Metformin

| Protein                          | Interaction Energy |
|---------------------------------|--------------------|
| Glucokinase                     | -4.6               |
| Glycogen phosphorylase          | -5.4               |
| Peroxisome proliferator-activated receptor gamma | -5.6               |
| Insulin receptor kinase         | -4.7               |
| Dipeptidyl peptidase (IV)       | -5                 |
| Protein Tyrosine Phosphatase 1B | -5.3               |
| α-glucosidase                   | -5.3               |
| Glycogen synthase kinase 3β     | -4.8               |

Glycogen phosphorylase: Tyr 280, Phe 285
Peroxisome proliferator-activated receptor gamma: His 323, Tyr 327, Tyr 473
Insulin receptor kinase: Asn 1137
Dipeptidyl peptidase (IV): Glu 205, Glu 206
Protein Tyrosine Phosphatase 1B: Ser 80, Ser 205, His 208
α-glucosidase: His 332
Glycogen synthase kinase 3β: Leu 343, Asp 345, Pro 346, Thr 356, His 381

**Figure 1:** Molecular interactions with Glucokinase a - Cpd-1, b - Cpd-2, c - Cpd-3, d - Glibenclamide, e - Metformin. The green color represents the amino acids in the receptor proteins involved in covalent interactions forming hydrogen bonds with the ligands.

**Material and Methods:**

**Preparation of receptors:**

The 3D X-ray crystallographic structures of the target proteins, Glucokinase (PDB ID: 1W98), Glycogen phosphorylase (PDB ID: 1W98), Dipeptidyl peptidase (IV) (PDB ID: 1W98), Protein Tyrosine Phosphatase 1B (PDB ID: 1W98), Insulin receptor kinase (PDB ID: 1IRK), Peroxisome proliferator-activated receptor gamma (PDB ID: IZGY), α-glucosidase (PDB ID: 3WY1), Glycogen synthase kinase 3β (PDB ID: 1Q4L) were obtained from Protein Data Bank (PDB) as shown in **Figure 9**. The receptors were prepared by removing the hetero-atoms and water molecules and adding polar hydrogen atoms using the Discovery Studio Visualizer 2017 R2 Client software.

**Preparation of ligands:**

The structures of triterpenoid compounds were drawn using ACD/Chemsketch tool and imported in mol2 format. The 3D structures of glibenclamide and metformin were downloaded from the PubChem database in SDF format. All the ligands were...
transformed to PDBQT file format and saved for PyRx-Virtual screening tool.

**Molecular Docking:**
The receptor proteins and ligands were docked using the PyRx Version 0.8 which enables preparing of binding site of the target protein and of screening of compound library. The results were visualized using Discovery Studio 2017 R2 Client software.

![Figure 4: Molecular interactions with Insulin receptor kinase](image)

**Results and discussion:**
The binding affinity scores and H bond interactions of the tetracyclic triterpenoid drugs with some known diabetes targets (Figure 9) were calculated and the results are shown in Table 2. The hot spots produced by 50 percent consensus residues in all of the compounds docked in the same active site areas of the targets. The compounds' docking patterns were similar to those of the authorized diabetic medications glibenclamide and metformin. The findings revealed that the compounds had the lowest binding energy and the highest affinity for binding to receptors. The covalent contacts generated by the ligand with the active site residues of the targets are used to calculate the docking's stability (Figures 1 to 8).

**Conclusion:**
We document the molecular docking analysis data of tetracyclic triterpenoids from Cassia fistula L. with targets for diabetes mellitus for further consideration.

![Figure 5: Molecular interactions with Dipeptidyl peptidase (IV)](image)

![Figure 6: Molecular interactions with Protein Tyrosine Phosphatase 1B](image)
Figure 7: Molecular interactions with α-glucosidase a- Cpd-1, b- Cpd-2, c- Cpd-3, d- Glibenclamide, e- Metformin. The green color represents the amino acids in the receptor proteins involved in covalent interactions forming hydrogen bonds with the ligands.

Figure 8: Molecular interactions with Glycogen synthase kinase 3β a- Cpd-1, b- Cpd-2, c- Cpd-3, d- Glibenclamide, e- Metformin. The green color represents the amino acids in the receptor proteins involved in covalent interactions forming hydrogen bonds with the ligands.

Figure 9: 3D structures of diabetic target proteins a- Glucokinase, b- Glycogen phosphorylase, c- Peroxisome proliferator-activated receptor gamma, d- Insulin receptor kinase, e- Dipeptidyl peptidase (IV), f- Protein Tyrosine Phosphatase 1B, g- α-glucosidase, h- Glycogen synthase kinase 3β.
References:

[1] Kazemi F et al. In Silico Pharmacol. 2020 9:1. [PMID: 33442533]
[2] Hamid K et al. Curr Top Med Chem. 2015 15:2406. [PMID: 26088353]
[3] Indu S et al. Molecules. 2021 26:6812. [PMID: 34833905]
[4] Khan A et al. In Silico Pharmacol. 2021 10:1. [PMID: 34926125]
[5] Balamurugan R et al. Eur J Med Chem. 2012 47:38. [PMID: 22078765]
[6] Herowati R & Widodo GP, Procedia Chem. 2014 13:63. [DOI: 10.1016/j.proche.2014.12.007]
[7] Prabhu S et al. Biomed Pharmacother. 2017 92:528. [PMID:28575810]
[8] Roy A et al. Bioinformation. 2020 16:748. [PMID: 34675460]
[9] Ganugapati J et al. Bioinformation. 2012 8:216. [PMID: 22493522]
[10] Zabidi NA et al. J Enzyme Inhib Med Chem. 2021 36:109. [PMID: 33249946]
[11] Kushwaha RN et al. Chem Biol Drug Des. 2015 85:439. [PMID: 25216392]
[12] Mphahlele MJ et al. Biomolecules. 2020 10:418. [PMID: 32156083]
[13] Kwon RH et al. Antioxidants (Basel). 2022 11:383. [PMID: 35204264]
[14] Tolmie M et al. J Diabetes. 2021 13:779. [PMID:33550683]
[15] Mor S & Sindhu S Med Chem Res. 2020 29:46. [PMID: 32435124]
[16] Motawi TMK et al. J Biochem Mol Toxicol. 2013 27:425. [PMID: 23784744]
[17] Natarajan A et al. BMC Complement Altern Med. 2015 15:73. [PMID: 25885803]